CTO PCI for Chronic Total Occlusions
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new approach to unblock heart arteries that are completely closed, known as chronic total occlusions (CTOs). The researchers aim to determine if planning a two-step procedure increases safety and success for patients. They also believe this method could enhance the patient experience. Individuals with high-risk blocked heart arteries requiring a specific procedure, known as chronic total occlusion (CTO) percutaneous coronary intervention (PCI), may be suitable for this trial. As an unphased trial, this study offers patients the chance to contribute to innovative research that could improve future treatment strategies.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you have a contraindication (reason not to use) to dual antiplatelet therapy, you may not be eligible to participate.
What prior data suggests that this procedure is safe?
Research has shown that chronic total occlusion percutaneous coronary intervention (CTO PCI) can be safe, though it carries some risks. One study found a success rate of 89.1% for this procedure. However, it also noted a higher chance of complications, including an increased risk of in-hospital death.
Another study found that CTO PCI significantly reduced the risk of dying from heart-related issues compared to other treatments. Thus, while risks exist, the procedure can offer important benefits.
Overall, CTO PCI is generally well-tolerated, especially when performed by experienced doctors. Discussing potential risks and benefits with a healthcare provider is important.12345Why are researchers excited about this trial?
Researchers are excited about CTO percutaneous coronary intervention (PCI) because it offers a new approach to treating chronic total occlusions in coronary arteries. Unlike traditional treatments like medication or bypass surgery, CTO PCI involves a minimally invasive procedure that can restore blood flow directly through the blocked artery. This technique uses specialized tools and techniques to navigate and open the blockage, potentially leading to quicker recovery times and less overall risk compared to more invasive surgeries. By offering a less invasive option, CTO PCI could significantly improve outcomes for patients with this challenging condition.
What evidence suggests that this planned investment procedure for CTO PCI could improve safety and efficacy?
Research has shown that chronic total occlusion (CTO) percutaneous coronary intervention (PCI), which participants in this trial will undergo, can relieve symptoms for patients with blocked heart arteries. Studies have found this procedure often succeeds, especially in experienced medical centers. For example, one study reported a success rate of 89.1%. Another study showed a 73% success rate, with patients experiencing improved heart function after four months. Although some risks exist during and after the procedure, CTO PCI can offer long-term benefits for many patients.15678
Who Is on the Research Team?
Margaret B Mcentegart, PhD
Principal Investigator
Golden Jubilee National Hospital
Anja Øksnes, MD
Principal Investigator
Haukeland University Hospital
Are You a Good Fit for This Trial?
This trial is for patients who can consent to the study, follow the schedule, and are planned for a high-risk CTO PCI according to European and American criteria. Details on who cannot participate are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Procedure
Participants undergo the initial stage of the planned investment procedure for CTO PCI
Staged Completion Procedure
Participants undergo the staged completion of the CTO PCI procedure
Follow-up
Participants are monitored for safety and effectiveness after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)
Chronic total occlusion(CTO) percutaneous coronary intervention (PCI) is already approved in European Union, United Kingdom, United States for the following indications:
- Coronary artery disease
- Chronic total occlusion
- Coronary artery disease
- Chronic total occlusion
- Coronary artery disease
- Chronic total occlusion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Haukeland University Hospital
Lead Sponsor
Golden Jubilee National Hospital
Collaborator